Tip os
Log ind
Novo Nordisk flag-version2.jpg

FDA panel sees cardiovascular benefits from Novo's Victoza

Top picks in English:

With an overwhelming majority, an independent advisory committee under the US drug agency FDA has found that Novo Nordisk’s Leader study provides substantial evidence of cardiovascular risk reduction in treatment with Victoza. The result opens up the opportunity for including the data on the product’s US label.


BY MARTIN HAVTORN PETERSEN
Offentliggjort 21.06.17 kl. 21:56

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

MSD fined for employee’s LinkedIn post

linkedin.jpg Top picks in English:

Sharing product-related news on the social media LinkedIn had consequences for an employee in the Danish unit of MSD. The post could be regarded as advertisement and has resulted in a fine from The Ethical Committee for the Pharmaceutical Industry.

Here is what Danish drug companies pay their workers

Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Leo Pharma announces new results for biologic hope

Top picks in English:

New phase III data from a study of one of Leo Pharma’s biologic drugs, Kyntheum, show significant benefits from long-term treatment with the drug.

Danish biotech company sold to Swedes

Top picks in English:

The Swedish company Ascelia, managed by a former Sunstone director, has acquired the biotech company Oncoral and its cancer candidate, which is currently being tested in phase I trials at Herlev Hospital in Denmark.

Onxeo loses half its market cap after failed cancer study

Top picks in English:

The Danish-French biotech company Onxeo did not succeed with a phase III trial with drug candidate Livataq in patients with hepatocellular carcinoma (HCC). Now, the share price has dropped by nearly 50 percent and several banks have downgraded the price target of the Onxeo share.

Danish hearing aid giants in global showdown

Top picks in English:

The world’s largest hearing device dealer, Amplifon, expresses concern over the entry into the retail market of manufacturers such as William Demant. GN Resound, on the other hand, receives praise and is expected to form even closer ties to its Italian collaborator.

Forsiden lige nu

9 ud af 10 EMA-ansatte vil ikke flytte til mindst populære ansøgerland

EMA.jpg Medicinal & Biotek:

Ansatte i EMA har vurderet de 19 kandidatlande ud fra, om de er interesserede i at flytte med, når agenturet fra 2019 flytter fra London.

Biogen henter ny Alzheimers-direktør hos Novo

Medicinal & Biotek:

Den nye chef for Biogens Alzheimers-division er en tidligere Novo medarbejder med mere end 30 års erfaring fra den danske virksomhed.

Medicinsalg handler om borgernes sundhed

Meninger:

Vi skal selvfølgelig have sunde forretninger, men medicinsalg handler ikke om tjene så mange penge som muligt. Det handler om at sikre, at borgerne får den rigtige behandling, skriver Anne Kahns, formand for Danmarks Apotekerforening, i denne klumme.

Pfizer føder nyt selskab med fire potentielle lægemidler

Medicinal & Biotek:

Amerikanske Pfizer står bag nyt spinout-selskab, der med trecifret million-investering i ryggen skal forsøge at bringe i første omgang fire potentielle lægemidler til markedet.

Amerikanere øger short-position i Bavarian-aktien

Medicinal & Biotek:

Amerikansk investeringsselskab har øget sit sats på kursfald for Bavarian Nordic-aktien.

AstraZeneca indgår immunonkologiaftale med NewLink

Medicinal & Biotek:

Det amerikanske biotekselskab NewLink Genetics skal nu teste sin eksperimentelle IDO-hæmmer med AstraZenecas PD-L1-hæmmer Imfinzi i patienter med bugspytkirtelkræft.

ANNONCE
ANNONCE


ANNONCE